Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. Its focus is to develop and commercialize SCENESSE (INN: afamelanotide) as a medicinal photoprotective solution for patients who are most severely affected by ambient light exposure and UV. The Company’s lead compound, SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the United States, Europe and Australia. The Company has obtained Orphan Drug Designations (ODDs) for afamelanotide for the indications porphyria (EPP) and solar urticaria (SU) in Europe and the United States. The Company’s CUV9900 is an alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue which the company intends will complement Clinuvel's lead product SCENESSE (afamelanotide). It belongs to the same family of molecules, known as melanocortins, as afamelanotide.